



(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/097423 A1

- (51) **International Patent Classification:** G01N 33/68
- (21) **International Application Number:** PCT/EP2004/004342
- (22) **International Filing Date:** 23 April 2004 (23.04.2004)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
60/465,484 25 April 2003 (25.04.2003) US
- (71) **Applicant (for all designated States except US):** GENOVA LTD.; Canon's Court, 22 Victoria Street, Hamilton, HM 12, Bermudas (BM).
- (71) **Applicant (for AT only):** NOVARTIS PHARMA GmbH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** BOUGUELERET, Lydie [FR/CH]; GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). CUSIN, Isabelle [FR/CH]; GeneProt, Inc., 2, rue Pre-de-la-Fontaine, CH-1217 Meyrin (CH).
- (74) **Agent:** GRUBB, Phillip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report

[Continued on next page]

- (54) Title:** SECRETED POLYPEPTIDE SPECIES REDUCED CARDIOVASCULAR DISORDERS

SEO ID NO:1

1 MLIVSVRLM YGSLAFLCAD TARDVASEF RKKWNKWALS RGKRELEMS SYPTGLADVK
61 AGPAOTLRP QDMGASRSP EDSSPDAARI RVKRYRQSM NFQGLRSGFC RFGTCTVQKL
121 AHQIYQPTDK DKDNVAPRSK ISPQGYGRRR RRLPEAGPG RTLSSKQPA HGAPAPPSGS
181 APHFL

SEO ID NO:2

1 ARLDVASEFR KKWNKWLNR GKRRLRMBSS YFGGLADVKA SPACTLIRPO DMTGASRSPE
61 DSSFDAARIR VKRYRQSMNN FQGLRSSGCR PGTCTVOKLA HQIYQFTDKD KDNVAPRSKI
121 SPOGYGRRRR RSLPEAGPCR TLVSSKPOAH GAPAPPSGSA PHFL

SEQ ID NO:3

ELRMSSSYPT GLADVKAGPA OTLIRPODMK GASRSPEDSS PDAARIRV

SEO ID NO:4

MSSSYPTGLA DVKAGPAOTL IRPODMK

SEO ID NO:5

MSSSYPTGLA DVK

SEO ID NO:6

AGPAQTLIRP QDMK

- (57) Abstract:** The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders.

WO 2004/097423 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.